TDTarjani Vivek Dave

Tarjani Vivek Dave

*This is an algorithmically generated author record based on publicly available information.

Tarjani Vivek Dave has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute Invasive Fungal Rhino Orbital Sinusitis: Imaging-Driven Stratification and Orbit-Sparing Therapeutic Paradigms

    by Tarjani V. Dave, Sumer Doctor, Sneha Bhopatkar, Prerna Sinha, Daniel Rootman, M Reza Vagefi

    Acute invasive fungal rhino-orbital sinusitis (AIFROS) is a fulminant, angioinvasive infection that can rapidly threaten vision, the orbit, and life. Traditional management has often favored radical orbital exenteration once orbital or apical disease is detected, based on the assumption that removal of orbital tissue limits intracranial spread. However, growing clinical and radiologic evidence suggests that disease biology, particularly tissue perfusion and vascular dissemination, may be more important than the anatomic extent of orbital involvement alone. This manuscript presents an imaging-driven, biologically grounded framework for managing AIFROS with an emphasis on orbit preservation whenever feasible. Contrast-enhanced magnetic resonance imaging is proposed as the central tool for assessing tissue viability, distinguishing viable inflamed tissue from localized or diffuse necrosis, and identifying intracranial vascular spread. This stratification supports targeted treatment using systemic antifungals, aggressive sinus debridement, transcutaneous retrobulbar amphotericin B injections, and selective orbital debridement, rather than routine exenteration. Particular attention is given to the orbital apex, where involvement does not necessarily mandate radical surgery. Instead, cavernous sinus disease, internal carotid artery involvement, and cerebral infarction emerge as stronger predictors of mortality. Contemporary evidence increasingly supports orbit-sparing management in selected patients without compromising survival. AIFROS should therefore be approached as a perfusion-driven disease, where treatment is tailored to tissue vitality and vascular behavior rather than surgical radicality alone.

  • Tear Metabolomics in Thyroid Eye Disease: Molecular Signatures, Disease Activity, and Therapeutic Implications

    by Tarjani V. Dave, Aditi Machina, Sumer Doctor, Prerna Sinha, Collynn Woeller, Alon Kahana, Raymond I. Cho, Francesco M. Quaranta-Leoni, Diego Strianese

    Thyroid eye disease (TED) is a complex autoimmune orbital disease where clinical assessment tools, such as the Clinical Activity Score, often fail to capture the underlying molecular transitions between active inflammation and permanent fibrosis. As the field moves toward precision medicine, tear film metabolomics has emerged as a powerful, noninvasive source of biomarkers that can decode the orbital microenvironment. This review synthesizes current evidence on the metabolic signatures of TED, highlighting the shift from traditional protein biomarkers to small-molecule metabolites, including lipids, amino acids, and oxidative stress products. The current literature provides evidence that alterations in amino acid metabolism, polyamine synthesis, acylcarnitine profiles, and other markers of oxidative stress indicate disease activity in TED. We explore how liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) have identified key dysregulated pathways—most notably in the ornithine-polyamine axis, with an increased putrescine-to-ornithine ratio correlating best with inflammatory activity. By bridging the gap between systemic thyroid dysfunction and localized ocular manifestations, tear metabolomics offers a promising noninvasive approach for biomarker development, disease stratification, and therapeutic decision-making in thyroid eye disease.

  • Open Globe Injuries with Concurrent Orbital Fractures – Clinical Settings and Factors Predicting Outcomes

    by Tarjani Vivek Dave, Prapti Praful Chheda, Anthony Vipin Das, Vivek Pravin Dave

    We describe the clinical settings and the factors predicting outcomes in open globe injuries with concurrent orbital fracturesRetrospective, consecutive, non-comparative study. All eyes from Januar...


  • Open Access

    Immunopathology of COVID-19 and its implications in the development of rhino-orbital-cerebral mucormycosis: a major review

    by Tarjani Vivek Dave, Akshay Gopinathan Nair, Joveeta Joseph, Suzanne K Freitag

    To present a literature review on various immunopathologic dysfunctions following COVID-19 infection and their potential implications in development of rhino-orbital-cerebral mucormycosis (ROCM).A ...


  • Two-Year Outcomes of Transcutaneous Non-Image Guided Bleomycin Sclerotherapy in Conjunctival Lymphatic Malformations: A Protocol-Based Management in 16 Eyes

    by Tarjani Vivek Dave, Priyanka Walvekar

    Objectives: To study the efficacy and the 2-year outcomes of treating conjunctival lymphatic malformations (LM) with protocol-based bleomycin sclerotherapy. Methods: A retrospective interventional study of 16 eyes with conjunctival LM treated with bleomycin sclerotherapy between December 2016 and 2019. A clinical resolution was assessed as poor (less than 25% decrease in size), fair (25%–50% decrease in size), good (50%–75% decrease in size), excellent (more than 75% decrease in size), and complete resolution. Results: Mean age at presentation was 18 ± 13.09 (15 years, 3 to 59 years) years. The conjunctival component was classified based on clinical appearance as conjunctival mass (12) and microcystic LM (4). Mean clock hours of involvement were 3.32 ± 5.29 clock hours (4, 2–9 clock hours). An average per session dose of 1.8 ± 0.3 IU (median 2 IU, range 1–2 IU) and a cumulative dose of 3 ± 1.5 IU (3, 1–6 IU) of bleomycin were injected over an average of 1.6 ± 0.7 (median 2, range 1–3) treatment sessions per patient. Excellent response was observed in 11 (69%) cases. A residual lesion requiring surgical debulking was noted in 1 case. Recurrence was noted in 2 (13%) cases one of which was treated with repeat sclerotherapy resulting in complete resolution. Adverse reactions included restricted extraocular motility in extreme gaze in 2 eyes (13%). Sustained tumor resolution was observed over a mean follow-up of 29.24 + 9.45 months (24, 24–38 months). Conclusions: Bleomycin sclerotherapy gives excellent response in conjunctival LMs and is an effective first-line therapy in these cases.


  • Demography, Clinical Settings and Outcomes in Evisceration with Implant: An Electronic Medical Records Driven Analytics of 2071 Cases

    by Tarjani Vivek Dave, Anthony Vipin Das, Samir Mohapatra, Oshin Bansal, Anasua Ganguly

    To describe the demography, clinical settings and outcomes in 2071 patients undergoing evisceration across a multi-tier ophthalmology hospital network and comparison of results with the global scen...


  • Open Access

    Evidence of dengue virus in eviscerated specimens of panophthalmitis secondary to dengue fever: A possible cause-effect phenomenon

    by Tarjani V Dave, Savitri Sharma, Vemu Lakshmi, Ashok Rangaiahgari, Somasheila I Murthy, Mohammad J Ali, Vivek P Dave, Rajeev R Pappuru

    Purpose: To report a retrospective series of three cases of infectious panophthalmitis post-dengue fever with ex vivo confirmation of dengue virus ribonucleic acid (RNA) in the tissues of the eye. Methods: Four eyes of three patients, who were diagnosed with panophthalmitis following dengue fever and who underwent evisceration, were included. All demographic and clinical data were recorded. The eviscerated samples were subjected to direct microscopy, culture for bacteria, fungi, and parasites, and molecular virology (dengue virus [DENV] NS1-specific reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay). Results: The time from the development of dengue fever to the occurrence of ocular symptoms was 4.33 ± 1.15 (median 5) days. DENV NS1 RNA, suggestive of the presence of the dengue virus, was confirmed in all evisceration specimens (uveal tissue, cornea). All the patients recovered completely from dengue fever and on follow-up had healthy eviscerated sockets. Conclusion: Demonstration of the DENV RNA in the eviscerated specimens of panophthalmitis following dengue fever implicates the DENV in the pathophysiology of the ocular infection.


  • Choroidal vascularity index in thyroid eye disease: comparison with controls and application in diagnosing non-inflammatory active disease

    by Tarjani Vivek Dave, Ganesh Babu Jonnadula, Prashanthi Lanka, Ramya Natarajan, Vivek Pravin Dave

    To report the differences in choroidal vascularity index (CVI) in thyroid eye disease (TED) and normals and its discriminatory value for differentiating various stages of TED.Prospective, cross-sec...


  • Open Access

    Choroidal Thickness in Thyroid Eye Disease: Comparison With Controls and Application in Diagnosing Non-Inflammatory Active Disease

    by Tarjani V. Dave, Ramya Natarajan, Rakshi Ugandhar Reddy, Anasua G. Kapoor, Vivek P. Dave

    Choroidal thickness is known to vary in various systemic diseases. In the current study, we aim to report the differences in choroidal thickness in thyroid eye disease (TED) and normals and its discriminatory value for differentiating various stages of TED. Prospective, cross-sectional, non-interventional imaging study. In an institutional practice, 102 eyes of 51 patients were included and divided into five groups: normal controls (C), inactive TED (I), active TED (A), non-inflammatory active TED (NIA) and systemic thyroid disorder but no TED (SYS). Choroidal images were acquired using the swept-source optical coherence tomography (Topcon DRI OCT Triton) with automatic layer segmentation which provided an automatic measurement of the subfoveal choroidal thickness and the mean in nine subfields based on the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. One-way analysis of variance (ANOVA), Youden index and area under the receiver operating characteristic curves (AUROC) were reported. Central choroidal thickness in the A group was 279±37.52 microns and in the NIA group was 302.5±59.22 microns. Both were comparable to each other and significantly higher than the C, I and SYS groups (p266 microns, the central sub-field had the strongest discriminatory potential to predict NIA. Choroidal thickness is greater in active and non-inflammatory active TED. The inner nasal and central ETDRS sub-fields have value in differentiating the non-inflammatory active TED eyes from the inactive eyes.